NU Skin Enterprises Inc. (NYSE: NUS) reported first-quarter results that were mixed relative to expectations, with revenue coming in near the low end of guidance while adjusted EPS remained within range. The company posted revenue of $320.6 million, adjusted net income of $6.8 million, and adjusted EPS of $0.14, compared to Stonegate Capital Partners' estimates of $329.7 million, $7.7 million, and $0.15, respectively. However, management commentary suggested early signs of field stabilization, particularly around the company's new Prysm iO platform, which could set the stage for a recovery in the second half of 2026.
Core Nu Skin gross margin improved 20 basis points year-over-year to 76.9%, reflecting cost discipline. However, adjusted operating margin fell to 3.6% from 6.4% a year ago, as the company continued investing in Prysm iO and emerging markets. The more important takeaway from the quarter was management's indication that brand affiliate confidence improved and new sales leaders grew year-over-year exiting the quarter. This suggests early field stabilization as Prysm iO training and leader engagement scale.
Prysm iO remains the core commercialization catalyst for NU Skin. The platform has seen nearly 2 million scans across over 30,000 devices, indicating early adoption. Additionally, subscription volume grew 5% year-over-year, suggesting the platform is beginning to improve customer engagement and recurring revenue quality. These metrics are critical as the company seeks to transition from a traditional direct-selling model to a more technology-enabled, subscription-based business.
Despite these positive signals, headline KPIs remain under pressure. Sales leaders, paid affiliates, and customers declined 13%, 8%, and 14% year-over-year, respectively. However, management cited improving brand affiliate confidence and year-over-year growth in new sales leaders exiting the quarter, which could be a leading indicator of a broader turnaround.
Looking ahead, NU Skin maintained its full-year 2026 revenue and adjusted EPS guidance of $1.35 billion to $1.50 billion and $0.80 to $1.20, respectively. This guidance implies confidence in a second-half improvement cadence, supported by broader Prysm iO adoption, the planned year-end launch in India, and continued cost discipline. For leaders in the business and technology sectors, NU Skin's experience underscores the challenges and opportunities of integrating advanced technology like AI-driven skin analysis into a traditional direct-sales model. The company's ability to stabilize its field force while scaling a new platform could provide lessons for other firms navigating digital transformation in consumer-facing industries.
For more details, the full announcement from Stonegate Capital Partners is available here.
